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Down syndrome (DS) is the most common form of congenital intellectual disability. Although DS involves
multiple disturbances in various tissues, there is little doubt that in terms of quality of life cognitive
impairmentisthemostseriousfacetandthereisnoeffectivetreatmentforthisaspectofthesyndrome.The
Ts65Dn mouse model of DS recapitulates multiple aspects of DS including cognitive impairment. Here the
Ts65Dn mouse model of DS was evaluated in an associative learning paradigm based on olfactory cues. In
contrast todisomiccontrols, trisomic miceexhibitedsignificant deficitsinolfactory learning. Treatment of
trisomic mice with the acetylcholinesterase inhibitor galantamine resulted in a significant improvement in
olfactory learning. Collectively, our study indicates that olfactory learning can be a sensitive tool for
evaluating deficits in associative learning in mouse models of DS and that galantamine has therapeutic
potential for improving cognitive abilities.
D
own syndrome (DS) was first described by the English physician John Langdon Down in 1866. It was
subsequently shown that this condition is caused by trisomy of chromosome (Chr) 21, which in the
majority of cases, is present in its entirety and is of maternal origin (reviewed in
1,2). Although DS involves
multiple disturbances in a relatively wide range of tissues there is little doubt that in terms of quality of life of the
person and parents, relatives and caretakers, cognitive impairment is the most serious aspect of this syndrome.
Mental retardation is evident as lower verbal and mental performance in the mild to moderate range and
individuals with DS show distinct delay in language development, deficits in auditory sequential processing
and verbal short-term memory
3. In addition to these impairments, as children with DS grow into adults, they
frequentlyincuranage-associatedneuronalloss,reminiscentofAlzheimer’sdisease
4-7.Bythefourthdecade,most
DS adults showsignsof early onsetAlzheimer’s, with the firstpresentation of neurofibrillary tanglesand neuritic
plaques in regions associated with learning and memory
4,8-10.
The Ts65Dn mouse is a segmental trisomy mouse model of DS containing a third copy of the distal region of
mouse Chr 16 that contains 94 genes orthologous to the DS critical region of human Chr 21
11. Ts65Dn mice
survivetoadulthoodandrecapitulatemultiplebiochemical,morphologicalandtranscriptionalaspectsofDSasit
occurs in humans
11-13 and has become an informative animal model of this syndrome (reviewed in
14). Although
Ts65Dn mice perform similarly to disomic controls in visual placing, balance, prehensile reflex, traction on a
horizontal bar, motor coordination
15, and olfaction orienting
16, neural cognitive deficits
17-19, motor and beha-
vioral abnormalities have been noted in these mice
4,20-22. Deficits in spatial learning and memory have been
especially prominent with significant impairment in both Morris water maze and radial maze performance
comparedtodisomiclittermatecontrols
13,15,23-25.Otherbehavioralabnormalitiesincludelocomotorhyperactivity
andstereotypicbehavior
24,26.Wewantedtoavoidthepotentialconfoundbetweenmotordeficitsandperformance
in spatial learning tasks, and also estimate learning using ethologically relevant cues.
Mice are macrosmatic animals, and use their acute sense of smell in many aspects of their lives that relate to
learning and memory, from communicating with conspecifics, finding food to avoiding predators
27,28. In spite of
the importance of this sensory modality, few studies have dealt with olfactory-based tasks in Ts65Dn mice
16.I n
thisstudy,wereportthefirstinvestigationofassociativeolfactorylearningperformanceintrisomicTs65Dnmice
anddisomiclittermatesinacomputerizedgo-no-goodordiscriminationtask.Weusedacomplementaryhidden
peanut butter finding test to assess whether changes in sensory-motor abilities could affect odor responses.
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brain cholinergic neurons
4,19,29 that correlates with their cognitive
decline
19, and the fact that deficits in cholinergic modulation in
Ts65Dn mice
19,29-31 are likely to affect olfactory learning
32,w e
hypothesized that the administration of an acetylcholinesterase
inhibitor drug galantamine hydrobromide would ameliorate
their olfactory learning behavior. We observed that trisomic mice
exhibited significant deficits in olfactory based learning compared to
disomic littermate controls and that this deficit could be rescued
by galantamine treatment. Collectively, our study indicates that
olfactory learning performance can be a sensitive tool for evaluating
deficits in associative learning in mouse models of DS and that
galantamine has therapeutic potential for improving cognition in
this syndrome.
Results
Trisomic Ts65Dn mice perform worse than controls in olfactory
learning. Ten disomic and ten trisomic mice were tested on the
olfactory learning tasks. Figures 1 A and B show representative
behavior of individual disomic and trisomic mice during the first
and second test-days in the odor detection task (Task A, citral vs.
mineral oil).
Figures 1 C and D show the average percent correct for the two
training days on each odor pair. A repeated measures ANOVA
(genotype*odor-pair*sex) indicates a significant effect of the geno-
type(F59.6;p50.007),aswellasanoverallsignificantimprovement
from day 1 to day 2 (F57.1; p50.018). There was a significant odor
pair*sex interaction (F56.8; p50.02). Post-hoc analyses reveal that
performance of disomic mice improved significantly from day 1 to
day2(58.1%to73.5%,p50.004,Tukey’sHSD).Thiswasnotthecase
fortrisomics(57.5%to61.7%,p50.75).PerformanceonDay2alone
was significantly better for disomics than trisomics (p50.034).
Collectively these results indicate that trisomics exhibit impaired
learning when compared to their disomic counterparts. To ensure
that the difference in learning did not stem from initial behavioral
differences when beginning the task, we performed a detailed beha-
vioral analysis on the first 5 blocks of the first day of learning (citral
vs.MineralOil).Therewasnosignificantdifferenceinthenumberof
licks between disomic and trisomic mice (on rewarded, unrewarded
trials or both: Supplemental Figure 1, Mann-Whitney U test: U59,
p50.46). This indicates that subsequent differences in learning were
not due to differences in the initial sampling strategy, or to differ-
ential emotional responses to the testing apparatus.
Galantamine treatment elicits better performance in olfactory
learningintrisomicmice.Wetestedtheeffectofachronictreatment
with galantamine or saline (shams) on the learning performance of
disomicandtrisomicmalemice(Fig.2).TheperformanceofTs65Dn
micewassignificantlyimprovedbychronicinjectionsofgalantamine.
Repeated measures ANOVA (treatment*odor-pair*day) reveals a
significant effect of the treatment (F55.1; p50.038), day (F55.1;
p50.02), and interaction day*odor-pair (F56.6; p50.02). The
improvement from D1 to D2 was only evident for the citral vs.
mineraloiltask(HSDTukeypost-Hoc:p50.007).Whilegalantamine
improved the overall performance (Tukey post-Hoc test p50.038),
theeffectcouldnotbenarroweddowntooneodorpair.Inspiteofan
apparent increase in performance, galantamine had no significant
effect on disomic mice (repeated measures ANOVA (treatment*
odor-pair*day; treatment effect: p50.121). Performance increased
Figure 1 | A and B. Examples of olfactory learning behavior of trisomic and disomic mice exposed to odor pairs A and B. Boldlines represent disomic
mice, and dashedlines thetrisomicmice.(A) Representative responses ofa singletrisomic(dashed linewithcirclemarkers)and disomic mice(continuous
linewithsquaremarkers)onthefirsttest-dayonodorpairA.(B)SameasA,butforthesecondtest-day.(C)Meancorrectresponsesforallblockswithineach
sectiononthefirstandseconddaysforodorpairA.(D)SameasC,butforodorpairB.Notethatthesemicedonotachievelearninginday1.Thisindicates
thatmiceoftheC3Hbackgroundtaketwodaysinachievinglearninginthistask.Mean(circleorsquaremarkers)andstandarderrorbarsareshownforeach
case. Significant differences are marked with one (P,0.05) or two asterisks (P,0.01). The y-axis shows the percent of correct responses.
www.nature.com/scientificreports
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groups (saline p50.035, galantamine p50.009).
Disomic and trisomic mice do not differ at performance in a pea-
nut butter finding test. Additionally, we performed a hidden peanut
butter finding experiment. Under saline treatment, both disomic and
trisomic mice needed approximately the same time to find the peanut
butter (mean6SEM588.37621.71 s, n58 and 99.68619.48 s, n510,
P50.17, T-Test). Similar latencies were achieved under galantamine
treatment (mean6SEM; disomics: 88.00622.88s, n57 and trisomics:
103.55620.27s,n59,P50.37,T-Test).Thetreatmenthadnoeffecton
either disomics or trisomics (T-test: p50.41 and p50.47, respectively).
Discussion
The observed olfactory learning performances of trisomic and diso-
mic mice in the olfactometer (Fig. 1) constitutes the first demonstra-
tionthatolfactory-based associative learning isnegatively affected in
Ts65Dnmice.Thepoorperformanceintheassociativelearningtask,
combined with documented deficits in spatial cognition, strongly
support a widespread effect of this trisomy on adaptive behaviors.
ThiswidearrayofcognitiveandsensorydeficitsvalidatetheTs65Dn
mouse as a valid model of Down Syndrome. The deficit in olfactory-
basedassociativelearningislikelyduetobothdeficitsinlearningand
odorperception.Thesedeficitsarewell-documentedinhuman:mild
to moderate mental retardation is evident in verbal and mental per-
formance
3 and olfactory deficits
33-38.
The presence of a third copy and presumed overexpression of
genes from Chr 21 in humans with DS, and Chr 16 in Ts65Dn
mouse
39, result in a complex perturbation of multiple processes
involved in neurological development and function
10. Many genes
expressing olfactory membrane receptors
40 are located on Chr 21 in
humans
41and Chr16-17 in mice
39,but the neurological effects of the
presumed overexpression of these olfactory genes is not known. On
one hand, olfactory receptor proteins are expressed from a single
allele, and an overrepresentation of the olfactory receptor genes is
unlikely to lead to an overexpression of olfactory receptor pro-
teins
42,43. However it is unknown if this overrepresentation of the
olfactory receptor genes could generate a down-regulation effect
on the expression of certain olfactory receptor proteins that could
decrease the sensitivity of the olfactory system to certain odorants.
Conversely, changes in expression of other genes such as ApoE epsi-
lon 4 could mediate an olfactory associative learning deficit
36.
Previous work has provided evidence of olfactory impairment in
patients with DS
34-36,38 and a role for cholinergic neurodegeneration
in this aspect of DS pathology is supported by the observation that
olfactory loss is also a common facet of Alzheimer’s disease
44,45.I ti s
difficult to dissociate the olfactory effects that could be caused by the
overrepresentation of olfactory receptor genes from those caused
by the neural degeneration associated with the early onset of
Alzheimer’s disease
34,35. This is a limitation of our approach, since
theolfactometer cannot separate learning and olfactoryimpairment.
Thus,wedonotknowhowchangesinproteinexpressioninducedby
DS affect olfactory learning and further studies will be required to
investigate these questions.
Another neurological consequence associated to the overexpres-
sion of genes in Ts65Dn mice is the diminished number of choliner-
gicneuronsonthebasalforebrain
19,46,whichlikelyisoneofthemain
causesof their learning deficits, and couldunderlie olfactory deficits.
Figure 2 | OlfactorylearningbehaviorofodorpairsAandBbydisomicandtrisomicmiceonchronictreatmentwithgalantamineorsaline. Olfactory
learning behavior of disomic (continuous lines) and trisomic (dashed lines) mice under chronic treatment with galantamine (square markers) or saline
(circle markers), and exposed to odor pairs A and B. (A) Mean number of correct responses of disomic mice on galantamine and saline for all blocks on
odorpairA.(B)SameasA,butfortrisomic mice. (C)SameasA,butforodorpairB.(D)SameasB,butforodor pairB.Mean(circleorsquaremarkers)
and standard error bars are shown for each case. Significant differences are marked with one (P,0.05) or two asterisks (P,0.01). The y-axis shows the
percent of correct responses.
www.nature.com/scientificreports
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cortex in a relatively widespread manner
47-49, and the acetylcholine
releasefromthesebasalforebraincholinergicneuronsmodulatesthe
cortical neurons and consequently the cerebral cortex
50. It is known
thatthemanifestationsofdementiainDShavebeenassociatedwitha
frontallobedysfunction
10,whichcouldbeassociatedwiththereduced
number of cholinergic neurons
19. In addition, decreased number of
cholinergic neurons in the horizontal diagonal band of Broca in the
basal forebrain would result in decreased projection of axons to the
olfactory bulb thereby affecting olfactory processing
32,51-53.
If the deficit in neural activity is due to decreased Ach neuron
expression, itshouldbecompensated byusing pharmacologicalacti-
vators of cholinergic neurons
54,55, like galantamine that boosts Ach
responsesintheneuralterminalsandnicotinicAchReceptors
56,57.In
this way, the galantamine activation of cholinergic neuron in the
basal forebrain that project to cortical neurons and olfactory areas
could conceivably activate the cholinergic neurons and possibly res-
cue some of the neurological and behavioral deficits associated with
DS. This possibility is consistent with previous work that has shown
that perinatal dietary supplementation with choline acts to signifi-
cantly improve cognition and emotion regulation in the Ts65Dn
mouse model
58.
In the present study we observed that the galantamine treatment
enabled trisomic mice to reach a performance level comparable with
that of disomic mice (Fig. 2). A significant improvement in the
percent of correct choices occurred in disomic and trisomic mice
under chronic treatment with galantamine. Galantamine treatment
improved the performance of trisomic mice in both tasks, while it
onlyimprovedtheperformanceofdisomicmiceonthemostdifficult
of them (task B). An explanation for the lack of effect of galantamine
on the performance of disomic mice on odor pair A comes from the
fact that they already achieved high scores on this task leaving little
scope for improvement. Thus, galantamine an acetylcholinesterase
inhibitor and an agonist of nicotinic receptors elicits improved per-
formance in an olfactory learning task in trisomic Ts65Dn mice.
Interestingly,inthepastnoimprovementinbehavioralperformance
in the Morris Water Maze was found in these mice after treatment
with the acetylcholine esterase inhibitor donepezil
59. In the future it
makes sense to test galantamine and donepezil in parallel experi-
ments in olfactory learning and MWM. Finally, in spite of the fact
that we cannot dissociate totally olfactory deficits from learning
deficits at a behavioral level, the positive action of galantamine in
our mice taken together with evidence from literature showing that
non-olfactory learning deficits in Ts65Dn are linked to a diminished
number of cholinergic neurons in the basal forebrain, reinforce the
hypothesis that the lower scores on the olfactory discrimination task
ismorelikelyanimpairmentintheacquisitionofthelearningrulein
consequence of the impaired basal forebrain-neocortex circuitry
than due to a malfunctioning of the olfactory system. Future studies
willhavetodeterminewhethertheseareolfactoryorsensorydeficits.
Galantamine has been used clinically to stabilize cognition in
patients with Alzheimer’s disease
60. Since DS has been strongly
linked with the early development of Alzheimer’s disease
10, and
autopsy of patients with Alzheimer’s disease revels lesions in the
cholinergic neurons of the basal forebrain
61, the results from the
present work indicate that galantamine has significant therapeutic
potential for alleviating learning deficits in humans with DS.
However, additional studies of galantamine treatment in Ts65Dn
mice and controls are needed to dissociate their transient and per-
manent effects prior to translation to a clinical trial.
Methods
Animals. The Ts65Dn subjects were either obtained directly from The Jackson
Laboratory (Bar Harbor, ME)(B6EiC3Sn a/A-Ts(17,16.65Dn)) or by mating
female carriers of the partial trisomy to hybrid males (C57Bl/6 Jeicher x C3H/HeSnJ
F1) obtained from The Jackson Laboratory. They were genotyped by fluorescence
in situ hybridization (FISH) using a probe for the centromere of mouse Chr 16
and Chr 17
62.
Inthisstudyweusedatotalof28trisomicTs65Dnmiceand26disomiclittermates.
45 male and 9 female mice between 3 and 6 months were used. 10 trisomic and 10
disomic naı ¨ve mice were used for the characterization of the olfactory learning
behavior in the go-no go task. Specifically for testing the effect of galantamine on
mouseolfactorybehavior,agroupof8disomicswastreatedwithdailyintraperitoneal
(i.p.)injectionsofgalantamineandanothergroupof8disomicswastreatedwithdaily
i.p. injections of saline vehicle. In the same way, a group of 9 trisomic Ts65Dn mice
was treated with saline vehicle and another 9 with galantamine. The same 34 mice
used for testing the effect of saline and galantamine on the go-no-go test were also
usedafteronthehiddenpeanutbutterfindingtest.Allexperimentswereapprovedby
the University of Colorado Anschutz Medical Center institutional animal care and
use committee and were performed according to the NIH standards for animal care
and use.
Operantconditioningbehavior.Weusedthebehavioralgo-nogoolfactorylearning
methods
63 detailed briefly as follows. In order to elicit motivation to obtain water
reward, animals were water-deprived to 80-85% of original body weight. Then mice
were trained during 3 days to poke in an odor sampling port and then respond by
licking the water delivery port in the presence of 10% citral in mineral oil to receive a
drop of water. Each trial is initiated by the mouse inserting its head in the odor-
sampling port and is followed by a 2.5 sec delivery of the odor. Reinforcement is
delivered if the mouse licks on the water-delivery tube at least once in each of the last
four 0.5 sec intervals of the 2.5 sec odor delivery period.
Next, the mice learned to respond to the S1 (rewarded) odor and not to the
S- (unrewarded) odor. S1 and S- trials are presented in a pseudo-random order with
the following restrictions: i) equal number of rewarded and unrewardedtrials in each
block of 20 trials and ii) no more than 3 of the same trials in a row.Each session has a
maximum of 10 blocks (200 trials). The session was terminated either when the
animal completed 10 blocks or when the animal became satiated and stopped ini-
tiatingtrials forovereightminutes. Todetermine thepercentageofcorrect responses
in each block of 20 trials the following formula was used:
PCR~100
HITSzCR
20

wherePCRarethepercentofcorrectresponses,HITSarerewardedtrialsinwhichthe
subject successfully obtained the reward, and CR are correct rejections - where the
animal restrained from licking on an unrewarded trial.
Olfactory stimuli for the go-no go task. Each subject was tested in two different
learning tasks:
Task A (odor detection): Citral 10% (S1, rewarded), Mineral oil (S-, unrewarded)
Task B (odor discrimination): 2-Heptanone 1% (S1); 3-Heptanone 1% (S-)
Task A is a simple discrimination task that used mineral oil alone, a diluent with
relatively weak odor as the unrewarded stimulus
64. A large difference in odor quality
wasusedintaskA(strongcitralvs.weakodormineraloil)becauseastrongdifference
in odor quality is necessary to when mice first learn to perform in the odor dis-
crimination task
63. Task B is a theoretically more challenging problem presenting
a new odor pair composed of 2-Heptanone 1%as the S1and 3-Heptanone 1% as the
S- (Odor Pair B). 7 disomic and 6 trisomic subjects unable to reach .70% correct in
the last two blocks of the last day of the 2 day training period by licking the water
delivery port in the presence of 10 % citral were removed from the study. For the
others, task A was performed followed by task B. In the olfactometer odors are
generated by mixing a 50 cc/min stream of air from the headspace of the odor-
saturator bottle with a 1950 cc/min stream of clean air, the odor experienced by the
mouse is 2.5% of the headspace concentration above the liquid odorant. Odors in the
saturator bottle were diluted in mineral oil.
Testing the effect of treatment with galantamine on go-no go olfactory learning
behavior. We tested the effects of galantamine treatment on olfactory learning
behavior in a separate group of naı ¨ve mice. During days when the mice were
undergoing olfactory learning in the go-no go task animals were injected intraper-
itoneally daily with 3 mg/g (drug/body weight) of galantamine hydrobromide (Tocris
Cookson Inc, Catalog number 0686) diluted in sterile saline, and tested 4 hours after
the injection
56,57. Daily chronic injections of galantamine hydrobromide started
during the 3-day training period in the presence of S1 only, and continued
throughout the go-no-go test in the presence of S1 and S-. Trisomics as well as
disomic mice were split into two groups, one receiving the galantamine, the other
receiving sham injections of sterile saline alone. Because performance in the
olfactometer tends to improve with time, it is not possible to compare the perform-
ance of the same individual on different treatments. The effect of galantamine was
therefore assessed in independent groups. The total length of treatment with galan-
tamine was 10 days.
Hiddenpeanutbutterfindingtest.Asimplediggingtestwasusedasanindependent
test of mouse olfactory ability in a task to find an odor reward hidden in the cage
65.
Mice of all 4 groups (both genotypes, both treatments) were given peanut butter, an
appetitivestimulustheywereallowedtoeat,onthedaybeforetothetestday.Then,on
the next day, mice were placed in the middle of a clean cage with a Petri dish with
www.nature.com/scientificreports
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latency to dig and find the peanut butter reward.
Statistics. The percent of correct responses per block were obtained for each animal,
and then the mean and standard error of the mean (SEM) were calculated for each
group. Statistical analyses for significance of differences in odor learning were per-
formed using the Statistica software (StatSoft, Inc.) and the Matlab Statistics Toolbox
(The Mathworks, Inc., Natick, MA). The mean percent correct for all blocks per
session (MPC) for each odor pair was analyzed and is shown in the figures. Groups
were compared using unpaired t tests and repeated measures analysis of variance
(ANOVA), using performance on day 1 and day 2 for each odor pair as the repeated
measures. Tukey’s Post-Hoc tests were then used, where p,0.05 was considered
statistically significant.
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